<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31905944</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Dec</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Steroid Therapy and Steroid Response in Autoimmune Pancreatitis.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">257</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21010257</ELocationID>
        <Abstract>
          <AbstractText>Autoimmune pancreatitis (AIP), a unique subtype of pancreatitis, is often accompanied by systemic inflammatory disorders. AIP is classified into two distinct subtypes on the basis of the histological subtype: immunoglobulin G4 (IgG4)-related lymphoplasmacytic sclerosing pancreatitis (type 1) and idiopathic duct-centric pancreatitis (type 2). Type 1 AIP is often accompanied by systemic lesions, biliary strictures, hepatic inflammatory pseudotumors, interstitial pneumonia and nephritis, dacryoadenitis, and sialadenitis. Type 2 AIP is associated with inflammatory bowel diseases in approximately 30% of cases. Standard therapy for AIP is oral corticosteroid administration. Steroid treatment is generally indicated for symptomatic cases and is exceptionally applied for cases with diagnostic difficulty (diagnostic steroid trial) after a negative workup for malignancy. More than 90% of patients respond to steroid treatment within 1 month, and most within 2 weeks. The steroid response can be confirmed on clinical images (computed tomography, ultrasonography, endoscopic ultrasonography, magnetic resonance imaging, and <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography). Hence, the steroid response is included as an optional diagnostic item of AIP. Steroid treatment results in normalization of serological markers, including IgG4. Short- and long-term corticosteroid treatment may induce adverse events, including chronic glycometabolism, obesity, an immunocompromised status against infection, cataracts, glaucoma, osteoporosis, and myopathy. AIP is common in old age and is often associated with diabetes mellitus (33-78%). Thus, there is an argument for corticosteroid therapy in diabetes patients with no symptoms. With low-dose steroid treatment or treatment withdrawal, there is a high incidence of AIP recurrence (24-52%). Therefore, there is a need for long-term steroid maintenance therapy and/or steroid-sparing agents (immunomodulators and rituximab). Corticosteroids play a critical role in the diagnosis and treatment of AIP.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Matsubayashi</LastName>
            <ForeName>Hiroyuki</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-7050-2351</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Endoscopy, Shizuoka Cancer Center 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka 411-8777, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Genetic Medicine Promotion, Shizuoka Cancer Center 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka 411-8777, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ishiwatari</LastName>
            <ForeName>Hirotoshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endoscopy, Shizuoka Cancer Center 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka 411-8777, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Imai</LastName>
            <ForeName>Kenichiro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endoscopy, Shizuoka Cancer Center 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka 411-8777, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kishida</LastName>
            <ForeName>Yoshihiro</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endoscopy, Shizuoka Cancer Center 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka 411-8777, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ito</LastName>
            <ForeName>Sayo</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endoscopy, Shizuoka Cancer Center 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka 411-8777, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hotta</LastName>
            <ForeName>Kinichi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endoscopy, Shizuoka Cancer Center 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka 411-8777, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yabuuchi</LastName>
            <ForeName>Yohei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endoscopy, Shizuoka Cancer Center 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka 411-8777, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoshida</LastName>
            <ForeName>Masao</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endoscopy, Shizuoka Cancer Center 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka 411-8777, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kakushima</LastName>
            <ForeName>Naomi</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endoscopy, Shizuoka Cancer Center 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka 411-8777, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takizawa</LastName>
            <ForeName>Kohei</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endoscopy, Shizuoka Cancer Center 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka 411-8777, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kawata</LastName>
            <ForeName>Noboru</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endoscopy, Shizuoka Cancer Center 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka 411-8777, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ono</LastName>
            <ForeName>Hiroyuki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endoscopy, Shizuoka Cancer Center 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka 411-8777, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013256">Steroids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4F4X42SYQ6</RegistryNumber>
          <NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081012" MajorTopicYN="N">Autoimmune Pancreatitis</DescriptorName>
          <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002386" MajorTopicYN="N">Cataract</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005901" MajorTopicYN="N">Glaucoma</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015212" MajorTopicYN="N">Inflammatory Bowel Diseases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009135" MajorTopicYN="N">Muscular Diseases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010024" MajorTopicYN="N">Osteoporosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010181" MajorTopicYN="N">Pancreatic Cyst</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013256" MajorTopicYN="N">Steroids</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">IgG4</Keyword>
        <Keyword MajorTopicYN="N">autoimmune pancreatitis</Keyword>
        <Keyword MajorTopicYN="N">corticosteroid</Keyword>
        <Keyword MajorTopicYN="N">treatment</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31905944</ArticleId>
        <ArticleId IdType="pmc">PMC6981453</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms21010257</ArticleId>
        <ArticleId IdType="pii">ijms21010257</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kanno A., Masamune A., Okazaki K., Kamisawa T., Kawa S., Nishimori I., Tsuji I., Shimosegawa T. Nationwide Epidemiological Survey of Autoimmune Pancreatitis in Japan in 2011. Pancreas. 2015;44:535–539. doi: 10.1097/MPA.0000000000000325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MPA.0000000000000325</ArticleId>
            <ArticleId IdType="pubmed">25815647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimosegawa T., Chari S.T., Frulloni L., Kamisawa T., Kawa S., Mino-Kenudson M., Kim M.-H., Kippel G., Lerch M.M., Lhr M., et al.  International Consensus Diagnostic Criteria for autoimmune pancreatitis—Guidelines of the International Association of Pancreatology. Pancreas. 2011;40:352–358. doi: 10.1097/MPA.0b013e3182142fd2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MPA.0b013e3182142fd2</ArticleId>
            <ArticleId IdType="pubmed">21412117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okazaki K., Tomiyama T., Mitsuyama T., Sumimoto K., Uchida K. Diagnosis and classification of autoimmune pancreatitis. Autoimmun. Rev. 2014;13:451–458. doi: 10.1016/j.autrev.2014.01.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2014.01.010</ArticleId>
            <ArticleId IdType="pubmed">24424184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawa S., Okazaki K., Kamisawa T., Shimosegawa T., Tanaka M., Working members of Research Committee for Intractable Pancreatic Disease and Japan Pancreas Society  Japanese consensus guidelines for management of autoimmune pancreatitis: II. Extrapancreatic lesions, differential diagnosis. J. Gastroenterol. 2010;45:355–369. doi: 10.1007/s00535-009-0197-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-009-0197-5</ArticleId>
            <ArticleId IdType="pubmed">20127119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamisawa T., Ryu J.K., Kim M.H., Okazaki K., Shimosegawa T., Chung J.B. Recent Advances in the Diagnosis and Management of Autoimmune Pancreatitis: Similarities and Differences in Japan and Korea. Gut Liver. 2013;7:394–400. doi: 10.5009/gnl.2013.7.4.394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5009/gnl.2013.7.4.394</ArticleId>
            <ArticleId IdType="pmc">PMC3724025</ArticleId>
            <ArticleId IdType="pubmed">23898377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ito T., Otsuki M., Itoi T., Shimosegawa T., Funakoshi A., Shiratori K., Naruse S., Kuroda Y. The Research Committee of Intractable Diseases of the Pancreas Pancreatic diabetes in a follow-up survey of chronic pancreatitis in Japan. J. Gastroenterol. 2007;42:291–297. doi: 10.1007/s00535-006-1996-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-006-1996-6</ArticleId>
            <ArticleId IdType="pubmed">17464458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirano K., Isogawa A., Tada M., Isayama H., Takahara N., Miyabayashi K., Mizuno S., Mohri D., Kawakubo K., Sasaki T., et al.  Long-Term Prognosis of Autoimmune Pancreatitis in Terms of Glucose Tolerance. Pancreas. 2012;41:691–695. doi: 10.1097/MPA.0b013e31823bcdee.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MPA.0b013e31823bcdee</ArticleId>
            <ArticleId IdType="pubmed">22249131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masuda A., Shiomi H., Matsuda T., Takenaka M., Arisaka Y., Azuma T., Kutsumi H. The relationship between pancreatic atrophy after steroid therapy and diabetes mellitus in patients with autoimmune pancreatitis. Pancreatology. 2014;14:361–365. doi: 10.1016/j.pan.2014.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pan.2014.07.005</ArticleId>
            <ArticleId IdType="pubmed">25278305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishimori I., Tamakoshi A., Kawa S., Tanaka S., Takeuchi K., Kamisawa T., Saisho H., Hirano K., Okamura K., Yanagawa N., et al.  Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: Findings from a nationwide survey in Japan. Pancreas. 2006;32:244–248. doi: 10.1097/01.mpa.0000202950.02988.07.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.mpa.0000202950.02988.07</ArticleId>
            <ArticleId IdType="pubmed">16628078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyamoto Y., Kamisawa T., Tabata T., Hara S., Kuruma S., Chiba K., Inaba Y., Kuwata G., Fujiwara T., Egashira H., et al.  Short and Long-Term Outcomes of Diabetes Mellitus in Patients with Autoimmune Pancreatitis after Steroid Therapy. Gut Liver. 2012;6:501–504. doi: 10.5009/gnl.2012.6.4.501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5009/gnl.2012.6.4.501</ArticleId>
            <ArticleId IdType="pmc">PMC3493733</ArticleId>
            <ArticleId IdType="pubmed">23170157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noguchi K., Nakai Y., Mizuno S., Isayama H., Hirano K., Kanai S., Nakamura T., Uchino R., Takahara N., Kogure H., et al.  Insulin secretion improvement during steroid therapy for autoimmune pancreatitis according to the onset of diabetes mellitus. J. Gastroenterol. 2019:1–7. doi: 10.1007/s00535-019-01615-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-019-01615-4</ArticleId>
            <ArticleId IdType="pubmed">31471733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamisawa T., Chari S.T., Lerch M.M., Kim M.-H., Gress T.M., Shimosegawa T. Recent advances in autoimmune pancreatitis: Type 1 and type 2. Gut. 2013;62:1373–1380. doi: 10.1136/gutjnl-2012-304224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2012-304224</ArticleId>
            <ArticleId IdType="pubmed">23749606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klöppel G., Detlefsen S., Chari S.T., Longnecker D.S., Zamboni G. Autoimmune pancreatitis: The clinicopathological characteristics of the subtype with granulocytic epithelial lesions. J. Gastroenterol. 2010;45:787–793. doi: 10.1007/s00535-010-0265-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-010-0265-x</ArticleId>
            <ArticleId IdType="pubmed">20549251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Kakushima N., Takizawa K., Tanaka M., Imai K., Hotta K., Ono H. Diagnosis of autoimmune pancreatitis. World J. Gastroenterol. 2014;20:16559–16569. doi: 10.3748/wjg.v20.i44.16559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v20.i44.16559</ArticleId>
            <ArticleId IdType="pmc">PMC4248199</ArticleId>
            <ArticleId IdType="pubmed">25469024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Detlefsen S., Zamboni G., Frulloni L., Feyerabend B., Braun F., Gerke O., Schlitter A.M., Esposito I., Klöppel G. Clinical features and relapse rates after surgery in type 1 autoimmune pancreatitis differ from type 2: A study of 114 surgically treated European patients. Pancreatology. 2012;12:276–283. doi: 10.1016/j.pan.2012.03.055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pan.2012.03.055</ArticleId>
            <ArticleId IdType="pubmed">22687385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Culver E.L., Sadler R., Simpson D., Cargill T., Makuch M., Bateman A.C., Ellis A.J., Collier J., Chapman R.W., Klenerman P., et al.  Elevated Serum IgG4 Levels in Diagnosis, Treatment Response, Organ Involvement, and Relapse in a Prospective IgG4-Related Disease UK Cohort. Am. J. Gastroenterol. 2016;111:733–743. doi: 10.1038/ajg.2016.40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ajg.2016.40</ArticleId>
            <ArticleId IdType="pubmed">27091321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deshpande V., Zen Y., Chan J.K., Yi E., Sato Y., Yoshino T., Klöppel G., Heathcote J.G., Khosroshahi A., Ferry J., et al.  Consensus statement on the pathology of IgG4-related disease. Mod. Pathol. 2012;25:1181–1192. doi: 10.1038/modpathol.2012.72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.2012.72</ArticleId>
            <ArticleId IdType="pubmed">22596100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serrero M., Abitbol V., Allez M., Amiot A., Barthet M., Beaugerie L., Bellaiche G., Bouguen G., Bouhnik Y., Bourreille A., et al.  Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases. Clin. Gastroenterol. Hepatol. 2018;16:59–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28782667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hart P.A., Levy M.J., Smyrk T.C., Takahashi N., Abu Dayyeh B.K., Clain J.E., Gleeson F.C., Pearson R.K., Petersen B.T., Topazian M.D., et al.  Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis (type 2 autoimmune pancreatitis): The Mayo Clinic experience. Gut. 2016;65:1702–1709. doi: 10.1136/gutjnl-2015-309275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2015-309275</ArticleId>
            <ArticleId IdType="pubmed">26085439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawa S., Okazaki K., Notohara K., Watanabe M., Shimosegawa T., Study Group for Pancreatitis Complicated with Inflammatory Bowel Disease organized by The Research Committee for Intractable Pancreatic Disease (Chairman: Tooru Shimosegawa) and The Research Committee for Intractable Inflammatory Bowel Disease (Chairman: Mamoru Watanabe), both of which are Supported by the Ministry of Health, Labour, and Welfare of Japan  Autoimmune pancreatitis complicated with inflammatory bowel disease and comparative study of type 1 and type 2 autoimmune pancreatitis. J. Gastroenterol. 2015;50:805–815. doi: 10.1007/s00535-014-1012-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-014-1012-5</ArticleId>
            <ArticleId IdType="pubmed">25399203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buijs J., Cahen D.L., Van Heerde M.J., Rauws E.A., de Buy Wenniger L.J., Hansen B.E., Biermann K., Verheij J., Vleggaar F.P., Brink M.A., et al.  The Long-Term Impact of Autoimmune Pancreatitis on Pancreatic Function, Quality of Life, and Life Expectancy. Pancreas. 2015;44:1065–1071. doi: 10.1097/MPA.0000000000000451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MPA.0000000000000451</ArticleId>
            <ArticleId IdType="pubmed">26355549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Sawai H., Kimura H., Yamaguchi Y., Tanaka M., Kakushima N., Takizawa K., Kadooka M., Takao T., Hebbar S., et al.  Characteristics of autoimmune pancreatitis based on serum IgG4 level. Dig. Liver Dis. 2011;43:731–735. doi: 10.1016/j.dld.2011.03.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dld.2011.03.006</ArticleId>
            <ArticleId IdType="pubmed">21515099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imai K., Matsubayashi H., Fukutomi A., Uesaka K., Sasaki K., Ono H. Endoscopic ultrasonography-guided fine needle aspiration biopsy using 22-gauge needle in diagnosis of autoimmune pancreatitis. Dig. Liver Dis. 2011;43:869–874. doi: 10.1016/j.dld.2011.05.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dld.2011.05.021</ArticleId>
            <ArticleId IdType="pubmed">21733766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Matsui T., Yabuuchi Y., Imai K., Tanaka M., Kakushima N., Sasaki K., Ono H. Endoscopic ultrasonography guided-fine needle aspiration for the diagnosis of solid pancreaticobiliary lesions: Clinical aspects to improve the diagnosis. World J. Gastroenterol. 2016;22:628–640. doi: 10.3748/wjg.v22.i2.628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v22.i2.628</ArticleId>
            <ArticleId IdType="pmc">PMC4716064</ArticleId>
            <ArticleId IdType="pubmed">26811612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanno A., Masamune A., Fujishima F., Iwashita T., Kodama Y., Katanuma A., Ohara H., Kitano M., Inoue H., Itoi T., et al.  Diagnosis of autoimmune pancreatitis by EUS-guided FNA using a 22-gauge needle: A prospective multicenter study. Gastrointest. Endosc. 2016;84:797–804.e1. doi: 10.1016/j.gie.2016.03.1511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gie.2016.03.1511</ArticleId>
            <ArticleId IdType="pubmed">27068878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang M.-C., Liang P.-C., Jan I.-S., Yang C.-Y., Tien Y.-W., Wei S.-C., Wong J.-M., Chang Y.-T. Comparison and validation of International Consensus Diagnostic Criteria for diagnosis of autoimmune pancreatitis from pancreatic cancer in a Taiwanese cohort. BMJ Open. 2014;4:e005900. doi: 10.1136/bmjopen-2014-005900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2014-005900</ArticleId>
            <ArticleId IdType="pmc">PMC4139642</ArticleId>
            <ArticleId IdType="pubmed">25138812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naitoh I., Nakazawa T., Hayashi K., Miyabe K., Shimizu S., Kondo H., Yoshida M., Yamashita H., Umemura S., Hori Y., et al.  Clinical Evaluation of International Consensus Diagnostic Criteria for Type 1 Autoimmune Pancreatitis in Comparison With Japanese Diagnostic Criteria 2011. Pancreas. 2013;42:1238–1244. doi: 10.1097/MPA.0b013e318293e628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MPA.0b013e318293e628</ArticleId>
            <ArticleId IdType="pubmed">24152949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamisawa T., Okazaki K., Kawa S., Shimosegawa T., Tanaka M., Research Committee for Intractable Pancreatic Disease and Japan Pancreas Society  Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J. Gastroenterol. 2010;45:471–477. doi: 10.1007/s00535-010-0221-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-010-0221-9</ArticleId>
            <ArticleId IdType="pubmed">20213336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubota K., Kamisawa T., Okazaki K., Kawa S., Hirano K., Hirooka Y., Uchida K., Shiomi H., Ohara H., Shimizu K., et al.  Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis: A long-term Japanese multicenter analysis of 510 patients. J. Gastroenterol. 2017;52:955–964. doi: 10.1007/s00535-016-1302-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-016-1302-1</ArticleId>
            <ArticleId IdType="pubmed">28062947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Kishida Y., Iwai T., Murai K., Yoshida M., Imai K., Yamamoto Y., Kikuyama M., Ono H. Transpapillary biliary stenting is a risk factor for pancreatic stones in patients with autoimmune pancreatitis. Endosc. Int. Open. 2016;4:E912–E917. doi: 10.1055/s-0042-111201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0042-111201</ArticleId>
            <ArticleId IdType="pmc">PMC4988851</ArticleId>
            <ArticleId IdType="pubmed">27540582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Matsui T., Ono H. Pancreatic Duct Drainage for the Treatment of a Huge Pancreatic Cyst Associated With Autoimmune Pancreatitis. Clin. Gastroenterol. Hepatol. 2015;13:e151–e152. doi: 10.1016/j.cgh.2015.03.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2015.03.020</ArticleId>
            <ArticleId IdType="pubmed">25818079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okazaki K., Chari S.T., Frulloni L., Lerch M.M., Kamisawa T., Kawa S., Kim M.-H., Levy P., Masamune A., Webster G., et al.  International consensus for the treatment of autoimmune pancreatitis. Pancreatol. 2017;17:1–6. doi: 10.1016/j.pan.2016.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pan.2016.12.003</ArticleId>
            <ArticleId IdType="pubmed">28027896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moon S.-H., Kim M.-H., Park D.H., Hwang C.Y., Park S.J., Lee S.S., Seo D.W., Lee S.K. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study. Gut. 2008;57:1704–1712. doi: 10.1136/gut.2008.150979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2008.150979</ArticleId>
            <ArticleId IdType="pubmed">18583399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Imai K., Kusumoto K., Ono H. Suspected autoimmune pancreatitis—An indication for steroid treatment? Dig. Liver Dis. 2010;42:525–526. doi: 10.1016/j.dld.2009.10.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dld.2009.10.001</ArticleId>
            <ArticleId IdType="pubmed">19910268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Furukawa H., Uesaka K., Sasaki K., Ono H., Hruban R.H. Autoimmune pancreatitis accompanied by cholecystitis, periaortitis and pseudotumors of the liver. Case Rep. Gastroenterol. 2008;2:155–161. doi: 10.1159/000125456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000125456</ArticleId>
            <ArticleId IdType="pmc">PMC3075136</ArticleId>
            <ArticleId IdType="pubmed">21490882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasahira N., Kawabe T., Nakamura A., Shimura K., Shimura H., Itobayashi E., Asada M., Shiratori Y., Omata M. Inflammatory pseudotumor of the liver and peripheral eosinophilia in autoimmune pancreatitis. World J. Gastroenterol. 2005;11:922–925. doi: 10.3748/wjg.v11.i6.922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v11.i6.922</ArticleId>
            <ArticleId IdType="pmc">PMC4250611</ArticleId>
            <ArticleId IdType="pubmed">15682495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell S.N., Rubio E., Loschner A.L. Clinical Review of Pulmonary Manifestations of IgG4-related Disease. Ann. Am. Thorac. Soc. 2014;11:1466–1475. doi: 10.1513/AnnalsATS.201403-128FR.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1513/AnnalsATS.201403-128FR</ArticleId>
            <ArticleId IdType="pubmed">25422997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Iwai T., Matsui T., Wada T., Kawata N., Ito H., Sasaki K., Uesaka K., Ono H. Pancreatic cystic lesions with atypical steroid response should be carefully managed in cases of autoimmune pancreatitis. J. Gastroenterol. Hepatol. 2016;31:270–276. doi: 10.1111/jgh.13051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jgh.13051</ArticleId>
            <ArticleId IdType="pubmed">26207936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Takagaki S., Otsubo T., Iiri T., Kobayashi Y., Yokota T., Shichijo K., Iwafuchi M., Kijima H. Pancreatic T-cell lymphoma with high level of soluble interleukin-2 receptor. J. Gastroenterol. 2002;37:863–867. doi: 10.1007/s005350200143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s005350200143</ArticleId>
            <ArticleId IdType="pubmed">12424573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Matsunaga K., Uesaka K., Fukutomi A., Sasaki K., Furukawa H., Ono H. A case of pancreatic carcinoma with suspected autoimmune pancreatitis. Clin. J. Gastroenterol. 2009;2:59–63. doi: 10.1007/s12328-008-0045-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12328-008-0045-9</ArticleId>
            <ArticleId IdType="pubmed">26191812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abarrategi A., Mariñas-Pardo L., Mirones I., Rincón E., Garcia-Castro J. Mesenchymal niches of bone marrow in cancer. Clin. Transl. Oncol. 2011;13:611–616. doi: 10.1007/s12094-011-0706-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12094-011-0706-x</ArticleId>
            <ArticleId IdType="pubmed">21865132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motosugi U., Ichikawa T., Yamaguchi H., Nakazawa T., Katoh R., Itakura J., Fujii H., Sato T., Araki T., Shimizu M. Small invasive ductal adenocarcinoma of the pancreas associated with lymphoplasmacytic sclerosing pancreatitis. Pathol. Int. 2009;59:744–747. doi: 10.1111/j.1440-1827.2009.02437.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1827.2009.02437.x</ArticleId>
            <ArticleId IdType="pubmed">19788620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamisawa T., Imai M., Chen P.Y., Tu Y., Egawa N., Tsuruta K., Okamoto A., Suzuki M., Kamata N. Strategy for Differentiating Autoimmune Pancreatitis From Pancreatic Cancer. Pancreas. 2008;37:e62–e67. doi: 10.1097/MPA.0b013e318175e3a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MPA.0b013e318175e3a0</ArticleId>
            <ArticleId IdType="pubmed">18815540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Uesaka K., Kanemoto H., Asakura K., Kakushima N., Tanaka M., Kimura H., Ono H. Soluble IL-2 Receptor, a New Marker for Autoimmune Pancreatitis. Pancreas. 2012;41:493–496. doi: 10.1097/MPA.0b013e31823a0d4c.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MPA.0b013e31823a0d4c</ArticleId>
            <ArticleId IdType="pubmed">22415671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Sasaki K., Nagata K., Kanemoto H., Kiuchi R., Ono H. Pancreatic carcinoma mimicking diffuse-type autoimmune pancreatitis: Important diagnostic role of pancreatic juice cytology using endoscopic naso-pancreatic drainage. J. Dig. Dis. 2012;13:287–290. doi: 10.1111/j.1751-2980.2012.00584.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1751-2980.2012.00584.x</ArticleId>
            <ArticleId IdType="pubmed">22500792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rankovic B., Limbaeck-Stokin C., Dokic M., Stanisavljević D., Volavšek M. Simultaneous occurrence of pancreatic mixed acinar-ductal adenocarcinoma and primary follicular lymphoma of the duodenum, accompanied by increased number of IgG4 plasma cells in tumor-free parenchyma as concomitant IgG4-related disease or reaction to tumor? A case report. Pol. J. Pathol. 2017;68:86–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28547986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X., Zhang P., Peng L., Fei Y., Zhang W., Feng R., Zhang W. Clinical characteristics of a concurrent condition of IgG4-RD and Castleman’s disease. Clin. Rheumatol. 2018;37:3387–3395. doi: 10.1007/s10067-018-4165-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-018-4165-4</ArticleId>
            <ArticleId IdType="pubmed">29948354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryu J.K., Chung J.B., Park S.W., Lee J.K., Lee K.T., Moon J.H., Cho K.B., Kang ., D.W .,  Hwang J.H., et al.  Review of 67 patients with autoimmune pancreatitis in Korea: A multicenter nationwide study. Histopathology. 2019;74:709–717. doi: 10.1111/his.13802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.13802</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danlos F.-X., Rossi G.M., Blockmans D., Emmi G., Kronbichler A., Durupt S., Maynard C., Luca L., Garrouste C., Lioger B., et al.  Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: A new overlap syndrome. Autoimmun. Rev. 2017;16:1036–1043. doi: 10.1016/j.autrev.2017.07.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2017.07.020</ArticleId>
            <ArticleId IdType="pubmed">28780079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawashima H., Utsugi A., Shibamiya A., Iida K., Mimura N., Ohashi H., Hase R., Kawakami M., Yanagisawa T., Hiraguri M. Consideration concerning similarities and differences between ANCA-associated vasculitis and IgG-4-related diseases: Case series and review of literature. Immunol. Res. 2019;67:99–107. doi: 10.1007/s12026-019-9070-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12026-019-9070-7</ArticleId>
            <ArticleId IdType="pubmed">30734199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Uesaka K., Sasaki K., Shimada S., Takada K., Ishiwatari H., Ono H. A Pancreatic Inflammatory Myofibroblastic Tumor with Spontaneous Remission: A Case Report with a Literature Review. Diagnostics. 2019;9:150.  doi: 10.3390/diagnostics9040150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/diagnostics9040150</ArticleId>
            <ArticleId IdType="pmc">PMC6963339</ArticleId>
            <ArticleId IdType="pubmed">31627359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nowak V., Agaimy A., Kristiansen G., Gütgemann I. Increased IgG4-positive plasma cells in nodular-sclerosing Hodgkin lymphoma: A diagnostic pitfall. Histopathology. 2019;76:244–250. doi: 10.1111/his.13965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.13965</ArticleId>
            <ArticleId IdType="pubmed">31373020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamisawa T., Shimosegawa T., Okazaki K., Nishino T., Watanabe H., Kanno A., Okumura F., Nishikawa T., Kobayashi K., Ichiya T., et al.  Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58:1504–1507. doi: 10.1136/gut.2008.172908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2008.172908</ArticleId>
            <ArticleId IdType="pubmed">19398440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Yoneyama M., Nanri K., Sugimoto S., Shinjo K., Kakushima N., Tanaka M., Ito S., Takao M., Ono H. Determination of steroid response by abdominal ultrasound in cases with autoimmune pancreatitis. Dig. Liver Dis. 2013;45:1034–1040. doi: 10.1016/j.dld.2013.06.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dld.2013.06.006</ArticleId>
            <ArticleId IdType="pubmed">23906519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Uesaka K., Kanemoto H., Aramaki T., Nakaya Y., Kakushima N., Ono H. Reduction of splenic volume by steroid therapy in cases with autoimmune pancreatitis. J. Gastroenterol. 2013;48:942–950. doi: 10.1007/s00535-012-0692-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-012-0692-y</ArticleId>
            <ArticleId IdType="pubmed">23076542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishikawa T., Itoh A., Kawashima H., Ohno E., Itoh Y., Nakamura Y., Hiramatsu T., Miyahara R., Ohmiya N., Haruta J., et al.  Peripancreatic vascular involvements of autoimmune pancreatitis. J. Gastroenterol. Hepatol. 2012;27:1790–1795. doi: 10.1111/j.1440-1746.2012.07248.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1746.2012.07248.x</ArticleId>
            <ArticleId IdType="pubmed">22849535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koshita S., Ito K., Fujita N., Noda Y., Kobayashi G., Horaguchi J., Kato Y., Yamashita Y., Kanno Y., Ogawa T. Localized autoimmune pancreatitis, 9 mm in size, without strictures of the main pancreatic duct. Gastrointest. Endosc. 2012;75:920–922. doi: 10.1016/j.gie.2011.05.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gie.2011.05.010</ArticleId>
            <ArticleId IdType="pubmed">21741640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujie S., Matsubayashi H., Ishiwatari H., Hazama H., Ito T., Sasaki K., Ono H. Intraductal Tubulopapillary Epithelial Proliferation Associated with Type 1 Autoimmune Pancreatitis. J. Gastrointestin Liver Dis. 2018;27:83–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29557419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakaji S., Hirata N., Fujii H., Iwaki K., Shiratori T., Kobayashi M., Wakasugi S., Ishii E., Takeyama H., Hoshi K. A case of focal autoimmune pancreatitis (AIP) mimicking an intraductal papillary mucinous neoplasm (IPMN) Clin. J. Gastroenterol. 2013;6:329–333. doi: 10.1007/s12328-013-0392-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12328-013-0392-z</ArticleId>
            <ArticleId IdType="pubmed">26181739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koshita S., Noda Y., Ito K., Kanno Y., Ogawa T., Masu K., Masaki Y., Kusunose H., Sakai T., Murabayashi T., et al.  Branch Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas Involving Type 1 Localized Autoimmune Pancreatitis with Normal Serum IgG4 Levels Successfully Diagnosed by Endoscopic Ultrasound-guided Fine-needle Aspiration and Treated without Pancreatic Surgery. Intern. Med. 2017;56:1163–1167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5491810</ArticleId>
            <ArticleId IdType="pubmed">28502930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaneko J., Matsubayashi H., Satoh T., Sato J., Takinami M., Ishiwatari H., Uesaka K., Abe M., Sasaki K., Ono H. Multilocular Cyst of Type 1 Autoimmune Pancreatitis Masquerading as Cancerization of Intraductal Papillary Mucinous Neoplasm. Intern. Med. 2019:3561-19. doi: 10.2169/internalmedicine.3561-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.3561-19</ArticleId>
            <ArticleId IdType="pmc">PMC7008053</ArticleId>
            <ArticleId IdType="pubmed">31484912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Kishida Y., Yoshida Y., Yoshida M., Tanaka Y., Igarashi K., Imai K., Ono H. Autoimmune pancreatitis with colonic stenosis: An unusual complication and atypical pancreatographic finding. BMC Gastroenterol. 2014;14:173.  doi: 10.1186/1471-230X-14-173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-230X-14-173</ArticleId>
            <ArticleId IdType="pmc">PMC4192343</ArticleId>
            <ArticleId IdType="pubmed">25280867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kasahara C., Wada Y., Matsuo M., Machida K., Matsushita A., Ito H. A Case of Pancreatitis with a Similar Course to Autoimmune Pancreatitis Occurring After Pembrolizumab Therapy in a Patient with Non-small Cell Lung Cancer. Haigan. 2018;58:344–348. doi: 10.2482/haigan.58.344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2482/haigan.58.344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiokawa M., Kodama Y., Yoshimura K., Kawanami C., Mimura J., Yamashita Y., Asada M., Kikuyama M., Okabe Y., Inokuma T., et al.  Risk of Cancer in Patients With Autoimmune Pancreatitis. Am. J. Gastroenterol. 2013;108:610–617. doi: 10.1038/ajg.2012.465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ajg.2012.465</ArticleId>
            <ArticleId IdType="pubmed">23318486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikeura T., Miyoshi H., Uchida K., Fukui T., Shimatani M., Fukui Y., Sumimoto K., Matsushita M., Takaoka M., Okazaki K. Relationship between autoimmune pancreatitis and pancreatic cancer: A single-center experience. Pancreatology. 2014;14:373–379. doi: 10.1016/j.pan.2014.04.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pan.2014.04.029</ArticleId>
            <ArticleId IdType="pubmed">25278307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishida M., Hodohara K., Yoshida K., Kagotani A., Iwai M., Yoshii M., Okuno H., Horinouchi A., Nakanishi R., Harada A., et al.  Occurrence of anaplastic large cell lymphoma following IgG4-related autoimmune pancreatitis and cholecystitis and diffuse large B-cell lymphoma. Int. J. Clin. Exp. Pathol. 2013;6:2560–2568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3816828</ArticleId>
            <ArticleId IdType="pubmed">24228121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asano J., Watanabe T., Oguchi T., Kanai K., Maruyama M., Ito T., Muraki T., Hamano H., Arakura N., Matsumoto A., et al.  Association Between Immunoglobulin G4–related Disease and Malignancy within 12 Years after Diagnosis: An Analysis after Longterm Followup. J. Rheumatol. 2015;42:2135–2142. doi: 10.3899/jrheum.150436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.150436</ArticleId>
            <ArticleId IdType="pubmed">26472416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto M., Takahashi H., Tabeya T., Suzuki C., Naishiro Y., Ishigami K., Yajima H., Shimizu Y., Obara M., Yamamoto H., et al.  Risk of malignancies in IgG4-related disease. Mod. Rheumatol. 2012;22:414–418. doi: 10.3109/s10165-011-0520-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/s10165-011-0520-x</ArticleId>
            <ArticleId IdType="pubmed">21894525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bledsoe J.R., Wallace Z.S., Stone J.H., Deshpande V., Ferry J.A. Lymphomas in IgG4-related disease: Clinicopathologic features in a Western population. Virchows Arch. 2018;472:839–852. doi: 10.1007/s00428-017-2286-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00428-017-2286-9</ArticleId>
            <ArticleId IdType="pubmed">29285637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahn S.S., Song J.J., Park Y.-B., Lee S.-W. Malignancies in Korean patients with immunoglobulin G4-related disease. Int. J. Rheum. Dis. 2017;20:1028–1035. doi: 10.1111/1756-185X.13093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1756-185X.13093</ArticleId>
            <ArticleId IdType="pubmed">28544157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Din L., Sheikh M., Kosaraju N., Smedby K.E., Bernatsky S., Berndt S.I., Skibola C.F., Nieters A., Wang S., McKay J.D., et al.  Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. Genet. Epidemiol. 2019;43:844–863. doi: 10.1002/gepi.22242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gepi.22242</ArticleId>
            <ArticleId IdType="pmc">PMC6763347</ArticleId>
            <ArticleId IdType="pubmed">31407831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masamune A., Nishimori I., Kikuta K., Tsuji I., Mizuno N., Iiyama T., Kanno A., Tachibana Y., Ito T., Kamisawa T., et al.  Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut. 2017;66:487–494. doi: 10.1136/gutjnl-2016-312049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2016-312049</ArticleId>
            <ArticleId IdType="pubmed">27543430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sah R.P., Chari S.T., Pannala R., Sugumar A., Clain J.E., Levy M.J., Pearson R.K., Smyrk T.C., Petersen B.T., Topazian M.D., et al.  Differences in Clinical Profile and Relapse Rate of Type 1 Versus Type 2 Autoimmune Pancreatitis. Gastroenterology. 2010;139:140–148. doi: 10.1053/j.gastro.2010.03.054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2010.03.054</ArticleId>
            <ArticleId IdType="pubmed">20353791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamisawa T., Okazaki K., Kawa S., Ito T., Inui K., Irie H., Nishino T., Notohara K., Nishimori I., Tanaka S., et al.  Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J. Gastroenterol. 2014;49:961–970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24639058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimizu S., Naitoh I., Nakazawa T., Hayashi K., Miyabe K., Kondo H., Nishi Y., Yoshida M., Umemura S., Hori Y., et al.  Correlation between long-term outcome and steroid therapy in type 1 autoimmune pancreatitis: Relapse, malignancy and side effect of steroid. Scand. J. Gastroenterol. 2015;50:1411–1418. doi: 10.3109/00365521.2015.1054424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/00365521.2015.1054424</ArticleId>
            <ArticleId IdType="pubmed">26061806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubota K., Kamisawa T., Hirano K., Hirooka Y., Uchida K., Ikeura T., Shiomi H., Ohara H., Shimizu K., Arakura N., et al.  Clinical course of type 1 autoimmune pancreatitis patients without steroid treatment: A Japanese multicenter study of 97 patients. J. Hepatobiliary Pancreat. Sci. 2018;25:223–230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29430861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawa S., Okazaki K., Kamisawa T., Kubo K., Ohara H., Hasebe O., Fujinaga Y., Irisawa A., Notohara K., Ito T., et al.  Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 II. Extrapancreatic lesions, differential diagnosis. J. Gastroenterol. 2014;49:765–784. doi: 10.1007/s00535-014-0944-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-014-0944-0</ArticleId>
            <ArticleId IdType="pubmed">24664402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soliman H., Vullierme M.-P., Maire F., Hentic O., Ruszniewski P., Lévy P., Rebours V. Risk factors and treatment of relapses in autoimmune pancreatitis: Rituximab is safe and effective. United Eur. Gastroenterol. J. 2019;7:1073–1083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6794684</ArticleId>
            <ArticleId IdType="pubmed">31662864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubota K., Watanabe S., Uchiyama T., Kato S., Sekino Y., Suzuki K., Mawatari H., Iida H., Endo H., Fujita K., et al.  Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids. J. Gastroenterol. 2011;46:834–842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21491208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu L., Xue H.-D., Zhang W., Wang Q., Tan B., Lai Y.-M., Zheng W.-Y., Asbach P., Hamm B., Denecke T., et al.  Pancreaticobiliary involvement in treated type 1 autoimmune pancreatitis: Imaging pattern and risk factors for disease relapse. Eur. J. Radiol. 2019;120:108673. doi: 10.1016/j.ejrad.2019.108673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejrad.2019.108673</ArticleId>
            <ArticleId IdType="pubmed">31550640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimizu K., Tahara J., Takayama Y., Akao J., Ajihara T., Nagao K., Shiratori K., Tokushige K. Assessment of the Rate of Decrease in Serum IgG4 Level of Autoimmune Pancreatitis Patients in Response to Initial Steroid Therapy as a Predictor of Subsequent Relapse. Pancreas. 2016;45:1–1346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27171510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawa S., Ito T., Watanabe T., Maruyama M., Hamano H., Maruyama M., Muraki T., Arakura N. The Utility of Serum IgG4 Concentrations as a Biomarker. Int. J. Rheumatol. 2012;2012:1–4. doi: 10.1155/2012/198314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2012/198314</ArticleId>
            <ArticleId IdType="pmc">PMC3321274</ArticleId>
            <ArticleId IdType="pubmed">22536256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Culver E.L., Sadler R., Bateman A.C., Makuch M., Cargill T., Ferry B., Aalberse R., Barnes E., Rispens T. Increases in IgE, Eosinophils, and Mast Cells Can be Used in Diagnosis and to Predict Relapse of IgG4-Related Disease. Clin. Gastroenterol. Hepatol. 2017;15:1444–1452.e6. doi: 10.1016/j.cgh.2017.02.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2017.02.007</ArticleId>
            <ArticleId IdType="pmc">PMC5592233</ArticleId>
            <ArticleId IdType="pubmed">28223204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lanzillotta M., Della-Torre E., Milani R., Bozzolo E., Bozzalla-Cassione E., Rovati L., Arcidiacono P.G., Partelli S., Falconi M., Ciceri F., et al.  Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse. Arthritis Res. 2018;20:222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6235221</ArticleId>
            <ArticleId IdType="pubmed">30285841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattoo H., Della-Torre E., Mahajan V.S., Stone J.H., Pillai S. Circulating Th2 memory cells in IgG4-related disease are restricted to a defined subset of subjects with atopy. Allergy. 2014;69:399–402. doi: 10.1111/all.12342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/all.12342</ArticleId>
            <ArticleId IdType="pmc">PMC3944385</ArticleId>
            <ArticleId IdType="pubmed">24382311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frulloni L., Lunardi C. Serum IgG4 in autoimmune pancreatitis: A marker of disease severity and recurrence? Dig. Liver Dis. 2011;43:674–675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21763225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamisawa T., Tu Y., Egawa N., Okamoto A., Kodama M., Kamata N. Can MRCP replace ERCP for the diagnosis of autoimmune pancreatitis? Abdom Imaging. 2009;34:381–384. doi: 10.1007/s00261-008-9401-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00261-008-9401-y</ArticleId>
            <ArticleId IdType="pubmed">18437450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Furukawa H., Maeda A., Matsunaga K., Kanemoto H., Uesaka K., Fukutomi A., Ono H. Usefulness of Positron Emission Tomography in the Evaluation of Distribution and Activity of Systemic Lesions Associated with Autoimmune Pancreatitis. Pancreatology. 2009;9:694–699. doi: 10.1159/000199439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000199439</ArticleId>
            <ArticleId IdType="pubmed">19684434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamisawa T., Egawa N., Nakajima H., Tsuruta K., Okamoto A., Kamata N., Funata N. Comparison of radiological and histological findings in autoimmune pancreatitis. Hepatogastroenterology. 2006;53:953–956.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17153461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shigekawa M., Yamao K., Sawaki A., Hara K., Takagi T., Bhatia V., Nishio M., Tamaki T., El-Amin H., Sayed Z.-A., et al.  Is (18)F-fluorodeoxyglucose positron emission tomography meaningful for estimating the efficacy of corticosteroid therapy in patients with autoimmune pancreatitis? J. Hepatobiliary Pancreat. Sci. 2010;17:269–274. doi: 10.1007/s00534-009-0172-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00534-009-0172-9</ArticleId>
            <ArticleId IdType="pubmed">19727541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okabe Y., Ishida Y., Kaji R., Sugiyama G., Yasumoto M., Naito Y., Toyonaga A., Tsuruta O., Sata M. Endoscopic ultrasonographic study of autoimmune pancreatitis and the effect of steroid therapy. J. Hepatobiliary Pancreat. Sci. 2012;19:266–273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21671062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho M.K., Moon S.-H., Song T.J., Kim R.E., Oh D.W., Park D.H., Lee S.S., Seo D.W., Lee S.K., Kim M.-H. Contrast-Enhanced Endoscopic Ultrasound for Differentially Diagnosing Autoimmune Pancreatitis and Pancreatic Cancer. Gut Liver. 2018;12:591–596. doi: 10.5009/gnl17391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5009/gnl17391</ArticleId>
            <ArticleId IdType="pmc">PMC6143455</ArticleId>
            <ArticleId IdType="pubmed">29699060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohno E., Hirooka Y., Kawashima H., Ishikawa T., Tanaka H., Sakai D., Ishizu Y., Kuzuya T., Nakamura M., Honda T. Feasibility and usefulness of endoscopic ultrasonography-guided shear-wave measurement for assessment of autoimmune pancreatitis activity: A prospective exploratory study. J. Med. Ultrason. 2009;46:425–433. doi: 10.1007/s10396-019-00944-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10396-019-00944-4</ArticleId>
            <ArticleId IdType="pmc">PMC6765472</ArticleId>
            <ArticleId IdType="pubmed">30993580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwon J.H., Kim J.H., Kim S.Y., Byun J.H., Kim H.J., Lee M.-G., Lee S.S. Differentiating focal autoimmune pancreatitis and pancreatic ductal adenocarcinoma: Contrast-enhanced MRI with special emphasis on the arterial phase. Eur. Radiol. 2019;29:5763–5771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31028441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi S.-Y., Kim S.H., Kang T.W., Song K.D., Park H.J., Choi Y.-H. Differentiating Mass-Forming Autoimmune Pancreatitis from Pancreatic Ductal Adenocarcinoma on the Basis of Contrast-Enhanced MRI and DWI Findings. Am. J. Roentgenol. 2016;206:291–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26797355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubota K., Fujita Y., Sato T., Sekino Y., Hosono K., Kobayashi N., Fujisawa N., Kagawa K., Fujisawa T., Matsuhashi N., et al.  Autoimmune pancreatitis associated with pancreatic cyst: How can we manage it? J. Hepatobiliary Pancreat. Sci. 2014;21:902–910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25214236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuraishi Y., Watanabe T., Muraki T., Ashihara N., Ozawa M., Nakamura A., Kanai K., Hamano H., Kawa S. Effectiveness of steroid therapy for pancreatic cysts complicating autoimmune pancreatitis and management strategy for cyst-related complications. Scand. J. Gastroenterol. 2019;54:773–779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31164010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donet J.A., Barkin J.A., Keihanian T., Nemeth Z., Barkin J.S. Pancreatic Pseudocysts and Parenchymal Necrosis in Patients With Autoimmune Pancreatitis. Pancreas. 2018;47:952–957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30028447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H., Kubota K. Pancreatic Cystic Lesions in Cases of Autoimmune Pancreatitis. Pancreas. 2019;48:e14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30640232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang K.A., Kim T.N., Lee S.H. Autoimmune pancreatitis complicated by an infected pseudocyst. Clin. J. Gastroenterol. 2010;3:168–173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26190126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto K., Itoi T., Sofuni A., Tsuchiya T., Tsuji S., Tanaka R., Tonozuka R., Honjo M., Mukai S., Kamada K., et al.  The Role of Endoscopic Ultrasound-guided Drainage for Autoimmune Pancreatitis-associated Pancreatic Cysts: A Report of Five Cases and a Literature Review. Intern. Med. 2018;57:1523–1531. doi: 10.2169/internalmedicine.9779-17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.9779-17</ArticleId>
            <ArticleId IdType="pmc">PMC6028677</ArticleId>
            <ArticleId IdType="pubmed">29434161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawakami H., Kuwatani M., Shinada K., Yamato H., Hirano S., Kondo S., Yonemori A., Itoh T., Matsuno Y., Asaka M. Autoimmune pancreatitis associated with hemorrhagic pseudocysts: A case report and literature review. Intern. Med. 2008;47:603–608. doi: 10.2169/internalmedicine.47.0731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.47.0731</ArticleId>
            <ArticleId IdType="pubmed">18379144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubota K., Wada T., Kato S., Mozaki Y., Yoneda M., Fujita K., Takahashi H., Inamori M., Abe Y., Kobayashi N., et al.  Highly Active State of Autoimmune Pancreatitis With Mikulicz Disease. Pancreas. 2010;39:e6–e10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19904224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zen Y., Fujii T., Sato Y., Masuda S., Nakanuma Y. Pathological classification of hepatic inflammatory pseudotumor with respect to IgG4-related disease. Mod. Pathol. 2007;20:884–894. doi: 10.1038/modpathol.3800836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.3800836</ArticleId>
            <ArticleId IdType="pubmed">17571078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hara N., Kawaguchi M., Takeda K., Zen Y. Retroperitoneal disorders associated with IgG4-related autoimmune pancreatitis. World J. Gastroenterol. 2014;20:16550–16558. doi: 10.3748/wjg.v20.i44.16550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v20.i44.16550</ArticleId>
            <ArticleId IdType="pmc">PMC4248198</ArticleId>
            <ArticleId IdType="pubmed">25469023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salvadori M., Tsalouchos A. Immunoglobulin G4-related kidney diseases: An updated review. World J. Nephrol. 2018;7:29–40. doi: 10.5527/wjn.v7.i1.29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5527/wjn.v7.i1.29</ArticleId>
            <ArticleId IdType="pmc">PMC5760510</ArticleId>
            <ArticleId IdType="pubmed">29359118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taniguchi T., Hamasaki A., Okamoto M. A case of suspected lymphocytic hypophysitis and organizing pneumonia during maintenance therapy for autoimmune pancreatitis associated with autoimmune thrombocytopenia. Endocr. J. 2006;53:563–566. doi: 10.1507/endocrj.K05-179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1507/endocrj.K05-179</ArticleId>
            <ArticleId IdType="pubmed">16849834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Detiger S.E., Karim F., Monserez D., Verdijk R., van Hagen M., Paridaens D., van Laar J. IgG4-related disease of the skull base: A case series of three patients with headache. World Neurosurg. 2019 doi: 10.1016/j.wneu.2019.10.111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.wneu.2019.10.111</ArticleId>
            <ArticleId IdType="pubmed">31669684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Detiger S.E., Karim A.F., Verdijk R.M., Van Hagen P.M., Van Laar J.A.M., Paridaens D. The treatment outcomes in IgG4-related orbital disease: A systematic review of the literature. Acta Ophthalmol. 2019;97:451–459. doi: 10.1111/aos.14048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/aos.14048</ArticleId>
            <ArticleId IdType="pubmed">30734497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van den Elshout-den U.D., Spoto C.P.E., De Boer M., Leiner T., Leavis H.L., Leguit R.J. First Report of IgG4 Related Disease Primary Presenting as Vertebral Bone Marrow Lesions. Front. Immunol. 2019;10:1910. doi: 10.3389/fimmu.2019.01910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01910</ArticleId>
            <ArticleId IdType="pmc">PMC6700296</ArticleId>
            <ArticleId IdType="pubmed">31456806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan S.K., Cheuk W., Chan K.T., Chan J.K. IgG4-related sclerosing pachymeningitis: A previously unrecognized form of central nervous system involvement in IgG4-related sclerosing disease. Am. J. Surg. Pathol. 2009;33:1249–1252. doi: 10.1097/PAS.0b013e3181abdfc2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0b013e3181abdfc2</ArticleId>
            <ArticleId IdType="pubmed">19561447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obiorah I., Hussain A., Palese C., Azumi N., Benjamin S., Ozdemirli M. IgG4-related disease involving the esophagus: A clinicopathological study. Dis. Esophagus. 2017;30:1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28881885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheuk W., Chan A.C.L., Lam W.-L., Chow S.-M., Crowley P., Lloydd R., Campbell I., Thorburn M., Chan J.K.C. IgG4-related Sclerosing Mastitis: Description of a New Member of the IgG4-related Sclerosing Diseases. Am. J. Surg. Pathol. 2009;33:1058–1064. doi: 10.1097/PAS.0b013e3181998cbe.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0b013e3181998cbe</ArticleId>
            <ArticleId IdType="pubmed">19384187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukuda M., Miyake T., Matsubara A., Ikai N., Tanaka E., Namura T., Wada Y., Noujima M., Moritani S., Murakami K., et al.  A Case of Sclerosing Mesenteritis Mimicking IgG4-related Disease. Intern. Med. 2019 doi: 10.2169/internalmedicine.3221-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.3221-19</ArticleId>
            <ArticleId IdType="pmc">PMC7056383</ArticleId>
            <ArticleId IdType="pubmed">31708540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yabuuchi Y., Matsubayashi H., Matsuzaki M., Shiomi A., Moriguchi M., Kawamura I., Ito I., Ono H. Colovesical fistula caused by glucocorticoid therapy for IgG4-related intrapelvic mass. World J. Clin. Cases. 2015;3:1000–1004. doi: 10.12998/wjcc.v3.i12.1000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12998/wjcc.v3.i12.1000</ArticleId>
            <ArticleId IdType="pmc">PMC4677080</ArticleId>
            <ArticleId IdType="pubmed">26677450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsui S. IgG4-related respiratory disease. Mod. Rheumatol. 2019;29:251–256. doi: 10.1080/14397595.2018.1548089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14397595.2018.1548089</ArticleId>
            <ArticleId IdType="pubmed">30474465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zen Y., Kitagawa S., Minato H., Kurumaya H., Katayanagi K., Masuda S., Niwa H., Fujimura M., Nakanuma Y. IgG4-positive plasma cells in inflammatory pseudotumor (plasma cell granuloma) of the lung. Hum. Pathol. 2005;36:710–717.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16084938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffmann J.C., Lin C.Y., Bhattacharyya S., Weinberg O.K., Chisholm K.M., Bayerl M., Cascio M., Venkataraman G., Allison K., Troxell M., et al.  Rosai-Dorfman Disease of the Breast With Variable IgG4+ Plasma Cells: A Diagnostic Mimicker of Other Malignant and Reactive Entities. Am. J. Surg. Pathol. 2019;43:1653–1660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31436555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tracht J., Reid M.D., Xue Y., Madrigal E., Sarmiento J.M., Kooby D., Alese O.B., Krasinskas A.M. Rosai-Dorfman Disease of the Pancreas Shows Significant Histologic Overlap With IgG4-related Disease. Am. J. Surg. Pathol. 2019;43:1536–1546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31368911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibata M., Matsubayashi H., Aramaki T., Uesaka K., Tsutsumi N., Sasaki K., Ono H. A case of IgG4-related hepatic inflammatory pseudotumor replaced by an abscess after steroid treatment. BMC Gastroenterol. 2016;16:89. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4970241</ArticleId>
            <ArticleId IdType="pubmed">27484098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Notohara K., Kamisawa T., Uchida K., Zen Y., Kawano M., Kasashima S., Sato Y., Shiokawa M., Uehara T., Yoshifuji H., et al.  Gastrointestinal manifestation of immunoglobulin G4-related disease: Clarification through a multicenter survey. J. Gastroenterol. 2018;53:845–853. doi: 10.1007/s00535-017-1420-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-017-1420-4</ArticleId>
            <ArticleId IdType="pubmed">29222587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Y., Chen L., Xu Y., Han Q., Yu B., Yuan Y., Zhao J., Yang Y., Chen J., Han F. Clinical and pathological features of patients with antineutrophil cytoplasmic antibody-associated vasculitides concomitant with IgG4-related disease. Int. J. Rheum. Dis. 2019;22:2143–2150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31631507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubota K., Iida H., Fujisawa T., Ogawa M., Inamori M., Saito S., Kakuta Y., Oshiro H., Nakajima A. Clinical Significance of Swollen Duodenal Papilla in Autoimmune Pancreatitis. Pancreas. 2007;35:e51–e60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18090232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohyama K., Koike H., Takahashi M., Kawagashira Y., Iijima M., Watanabe H., Sobue G. Immunoglobulin G4-related pathologic features in inflammatory neuropathies. Neurology. 2015;85:1400–1407. doi: 10.1212/WNL.0000000000002039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002039</ArticleId>
            <ArticleId IdType="pubmed">26408495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anan R., Akiyama M., Kaneko Y., Kikuchi J., Suzuki K., Matsubara S., Takeuchi T. Polymyositis with elevated serum IgG4 levels and abundant IgG4+ plasma cell infiltration: A case report and literature review. Medicine. 2017;96:e8710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5728745</ArticleId>
            <ArticleId IdType="pubmed">29310344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato Y., Takeuchi M., Takata K., Ohno K., Iwaki N., Orita Y., Goto N., Hida A.I., Iwamoto T., Asano N., et al.  Clinicopathologic analysis of IgG4-related skin disease. Mod. Pathol. 2013;26:523–532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23174935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamasue M., Nureki S.-I., Matsumoto H., Kan T., Hashimoto T., Ushijima R., Usagawa Y., Kadota J.-I. Corticosteroid Therapy for a Patient with Relapsing Polychondritis Complicated by IgG4-Related Disease. Tohoku J. Exp. Med. 2016;239:223–230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27396510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sawai H., Matsubayashi H., Tanaka M., Yamaguchi Y., Ono H. A case of autoimmune pancreatitis with metachronous appearance of idiopathic thrombocytopenic purpura. Clin. J. Gastroenterol. 2010;3:243–247. doi: 10.1007/s12328-010-0166-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12328-010-0166-9</ArticleId>
            <ArticleId IdType="pubmed">26190329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okazaki K., Yanagawa M., Mitsuyama T., Uchida K. Recent Advances in the Concept and Pathogenesis of IgG4-Related Disease in the Hepato-Bilio-Pancreatic System. Gut Liver. 2014;8:462–470. doi: 10.5009/gnl14107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5009/gnl14107</ArticleId>
            <ArticleId IdType="pmc">PMC4164252</ArticleId>
            <ArticleId IdType="pubmed">25228969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nayar M., Charnley R., Scott J., Haugk B., Oppong K. Autoimmune pancreatitis with multiorgan involvement. A case of pericardial involvement. JOP. 2009;10:539–542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19734633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horie K., Tada N., Yamaguchi K., Inazawa K., Endo M., Inoue N. Immunoglobulin G4-related constrictive pericarditis identified by cytological examination of pericardial effusion: A case report. J. Med Case Rep. 2016;10:359. doi: 10.1186/s13256-016-1159-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13256-016-1159-1</ArticleId>
            <ArticleId IdType="pmc">PMC5175317</ArticleId>
            <ArticleId IdType="pubmed">27998302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tajima M., Nagai R., Hiroi Y. IgG4-Related Cardiovascular Disorders. Int. Hear. J. 2014;55:287–295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24898599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alharbi A., Almadi M., Szilagyi A. An Unusual Cause of Upper Gastrointestinal Bleeding. Gastroenterology. 2012;142:211–413. doi: 10.1053/j.gastro.2011.02.075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2011.02.075</ArticleId>
            <ArticleId IdType="pubmed">22192427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoes J.N., Jacobs J.W., Verstappen S.M., Bijlsma J.W., Van der Heijden G.J. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: A meta-analysis. Ann. Rheum. Dis. 2009;68:1833–1838. doi: 10.1136/ard.2008.100008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2008.100008</ArticleId>
            <ArticleId IdType="pubmed">19066177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ito T., Nakamura T., Fujimori N., Niina Y., Igarashi H., Oono T., Uchida M., Kawabe K., Takayanagi R., Nishimori I., et al.  Characteristics of pancreatic diabetes in patients with autoimmune pancreatitis. J. Dig. Dis. 2011;12:210–216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21615876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee H.W., Moon S.-H., Kim M.-H., Cho D.H., Jun J.H., Nam K., Song T.J., Park D.H., Lee S.S., Seo D.-W., et al.  Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis: Long-term follow-up results after steroid therapy with short-duration maintenance treatment. J. Gastroenterol. 2018;53:967–977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29362937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura A., Ozawa M., Watanabe T., Ito T., Muraki T., Hamano H., Koinuma M., Kawa S. Predictive Factors for Autoimmune Pancreatitis Relapse After 3 Years of Maintenance Therapy. Pancreas. 2018;47:1337–1343. doi: 10.1097/MPA.0000000000001173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MPA.0000000000001173</ArticleId>
            <ArticleId IdType="pubmed">30286015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xin L., Meng Q.Q., Hu L.H., Lin H., Pan J., Hao L., Liu P.P., Qian W., Wang L.W., Li Z.S. Prediction and Management for Relapse of Type 1 Autoimmune Pancreatitis After Initial Steroid Treatment: A Long-Term Follow-up From China. Pancreas. 2018;47:1110–1114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30142120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miki M., Fujimori N., Oono T., Kawabe K., Ohno A., Matsumoto K., Teramatsu K., Tachibana Y., Ogawa Y. Relapse patterns and predictors of IgG4-related diseases involved with autoimmune pancreatitis: A single-center retrospective study of 115 patients. J. Dig. Dis. 2019;20:152–158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30701685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishii Y., Serikawa M., Sasaki T., Fujimoto Y., Yamaguchi A., Ogawa T., Noma B., Okazaki A., Yukutake M., Ishigaki T., et al.  Impact of sclerosing dacryoadenitis/sialadenitis on relapse during steroid therapy in patients with type 1 autoimmune pancreatitis. Scand. J. Gastroenterol. 2019;54:259–264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30915865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubota K., Iida H., Fujisawa T., Yoneda M., Inamori M., Abe Y., Kirikoshi H., Saito S., Ohshiro H., Kakuta Y., et al.  Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest. Endosc. 2007;66:1142–1151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18061714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyazawa M., Takatori H., Shimakami T., Kawaguchi K., Kitamura K., Arai K., Matsuda K., Sanada T., Urabe T., Inamura K., et al.  Prognosis of type 1 autoimmune pancreatitis after corticosteroid therapy-induced remission in terms of relapse and diabetes mellitus. PLoS ONE. 2017;12:e0188549.  doi: 10.1371/journal.pone.0188549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0188549</ArticleId>
            <ArticleId IdType="pmc">PMC5699801</ArticleId>
            <ArticleId IdType="pubmed">29166415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tacelli M., Celsa C., Magro B., Barresi L., Guastella S., Capurso G., Frulloni L., Cabibbo G., Cammà C. Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol. 2019;17:1061–1072. doi: 10.1016/j.cgh.2018.09.051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2018.09.051</ArticleId>
            <ArticleId IdType="pubmed">30312787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohno Y., Kumagi T., Yokota T., Azemoto N., Tanaka Y., Tange K., Inada N., Miyata H., Imamura Y., Koizumi M., et al.  Early pancreatic volume reduction on CT predicts relapse in patients with type 1 autoimmune pancreatitis treated with steroids. Orphanet J. Rare Dis. 2016;11:103. doi: 10.1186/s13023-016-0487-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13023-016-0487-y</ArticleId>
            <ArticleId IdType="pmc">PMC4964064</ArticleId>
            <ArticleId IdType="pubmed">27465035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hart P.A., Topazian M.D., Witzig T.E., Clain J.E., Gleeson F.C., Klebig R.R., Levy M.J., Pearson R.K., Petersen B.T., Smyrk T.C., et al.  Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: The Mayo Clinic experience. Gut. 2013;62:1607–1615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22936672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akiyama M., Takeuchi T. IgG4-Related Disease: Beyond Glucocorticoids. Drugs Aging. 2018;35:275–287. doi: 10.1007/s40266-018-0534-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40266-018-0534-6</ArticleId>
            <ArticleId IdType="pubmed">29546609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsushita M., Ikeura T., Fukui T., Uchida K., Okazaki K. Refractory autoimmune pancreatitis: Azathioprine or steroid pulse therapy? Am. J. Gastroenterol. 2008;103:1834–1835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18691195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rovati L., Lanzillotta M., Bozzolo E., Arcidiacono P.G., Falconi M., Dagna L., Della-Torre E. Methotrexate as Induction of Remission Therapy for Type 1 Autoimmune Pancreatitis. Am. J. Gastroenterol. 2019;114:831–833. doi: 10.14309/ajg.0000000000000232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/ajg.0000000000000232</ArticleId>
            <ArticleId IdType="pubmed">30998520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buechter M., Klein C.G., Kloeters C., Schlaak J.F., Canbay A., Gerken G., Kahraman A. Tacrolimus as a Reasonable Alternative in a Patient with Steroid-Dependent and Thiopurine-Refractory Autoimmune Pancreatitis with IgG4-Associated Cholangitis. Z. Gastroenterol. 2014;52:564–568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24905108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lazarevic I., Banko A., Miljanovic D., Cupic M. Immune-Escape Hepatitis B Virus Mutations Associated with Viral Reactivation upon Immunosuppression. Viruses. 2019;11:778.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6784188</ArticleId>
            <ArticleId IdType="pubmed">31450544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsushita M., Yamashina M., Ikeura T., Shimatani M., Uchida K., Takaoka M., Okazaki K. Effective steroid pulse therapy for the biliary stenosis caused by autoimmune pancreatitis. Am. J. Gastroenterol. 2007;102:220–221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17278279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sugimoto M., Takagi T., Suzuki R., Konno N., Watanabe K., Nakamura J., Kikuchi H., Waragai Y., Asama H., Takasumi M., et al.  Efficacy of Steroid Pulse Therapy for Autoimmune Pancreatitis Type 1: A Retrospective Study. PLoS ONE. 2015;10:e0138604. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4575182</ArticleId>
            <ArticleId IdType="pubmed">26381760</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
